[Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms].

INTRODUCTION Estimation of malignancy in thyroid follicular neoplasms is a common diagnostic problem, thus revealing of differences in expression of some antigens in both benign and malignant lesions seems to be essential. The aim of this study is to evaluate the immunohistochemical expression of CD15, galectin-3 and HBME-1 in follicular adenomas and carcinomas. MATERIAL AND METHODS Samples of 38 follicular adenomas (23 "classical", 5 with intracapsular invasion, 10 oncocytic) and 15 follicular carcinomas (9 "classic", 6 oncocytic) were stained immunohistochemically with anti-CD15, galectin-3 and HBME-1. RESULTS In the whole group we found statistically significant differences in CD15 expression between follicular adenomas and carcinomas. "Classic" follicular carcinomas (without oncocytic tumors) showed stronger CD15 and HBME- 1 expression than "classic" adenomas. Adenomas with intracapsular invasion differed from "classic" adenomas only in HBME-1 expression. In oncocytic tumors the expression of examined antigens was similar. CONCLUSIONS 1. In the group of nonoxyphilic tumors positive reaction with HBME-1 was more common in adenomas with intracapsular invasion and carcinomas, but positive reaction with anti-CD15--only in carcinomas. We suggest that reactivity with these antibodies could mark malignancy. 2. Oncocytic tumors had similar expression of CD15 and HBME-1 and galectin-3.

[1]  Mi-Jung Kim,et al.  Diagnostic Utility of Galectin-3 in Aspirates of Thyroid Follicular Lesions , 2006, Acta Cytologica.

[2]  J. Collet,et al.  Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples , 2005, British Journal of Cancer.

[3]  K. Metze,et al.  Usefulness of HBME‐1, cytokeratin 19 and galectin‐3 immunostaining in the diagnosis of thyroid malignancy , 2005, Histopathology.

[4]  A. Miyauchi,et al.  Galectin‐3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma , 2005, Pathology.

[5]  L. Mills,et al.  Galectin‐3 is not useful in thyroid FNA , 2005, Cytopathology : official journal of the British Society for Clinical Cytology.

[6]  A. Miyauchi,et al.  HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. , 2005, Anticancer research.

[7]  H. Nagaraja,et al.  Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors , 2005, Modern Pathology.

[8]  S. Johnson,et al.  Galectin‐3 does not reliably distinguish benign from malignant thyroid neoplasms , 2004, Histopathology.

[9]  J. Sulkes,et al.  Diagnostic value of galectin‐3 as a marker for malignancy in follicular patterned thyroid lesions , 2004, Head & neck.

[10]  M. Papotti,et al.  Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid , 2004, Virchows Archiv.

[11]  M. Papotti,et al.  Galectin-3: Presurgical marker of thyroid follicular epithelial cell-derived carcinomas , 2004, Journal of endocrinological investigation.

[12]  M. Miettinen,et al.  Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours , 1996, Virchows Archiv.

[13]  R. Gaffney,et al.  Galectin-3 Expression in Hyalinizing Trabecular Tumors of the Thyroid Gland , 2003, The American journal of surgical pathology.

[14]  T. Koshikawa,et al.  HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. , 2003, Endocrine journal.

[15]  J. Sygut,et al.  Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma. , 2003, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[16]  Z. Baloch,et al.  Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. , 2002, Archives of pathology & laboratory medicine.

[17]  K. Mai,et al.  Reduced HBME‐1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma‐related neoplastic lesions with Hürthle cell and/or apocrine‐like changes , 2002, Histopathology.

[18]  E. Paal,et al.  A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature , 2001, Cancer.

[19]  A. Longatto-Filho,et al.  Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas , 2001, Endocrine pathology.

[20]  S. Natsugoe,et al.  Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. , 2000, Human pathology.

[21]  M. P. Martegani,et al.  Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.